XML 31 R16.htm IDEA: XBRL DOCUMENT
v3.25.1

Stock-Based Compensation Plans | 12 Months Ended
--- | ---
Dec. 31, 2024
Share-Based Payment Arrangement [Abstract] |
Stock-Based Compensation Plans | Stock-Based Compensation Plans. The Company has two stock-based compensation plans (the 2006 Stock Incentive Plan and the 2016 Equity Incentive Option Plan) under which equity compensation has been granted to directors, officers and key employees. The 2016 plan permits the grant of stock options, stock appreciation rights, restricted stock awards, restricted stock units, or stock awards. The options awarded under the plans have similar characteristics. All stock options are non-qualified and expire ten years from the date of grant. Stock based compensation awarded to directors, officers and employees are exercisable immediately or become exercisable in cumulative installments of 20% or 25% at the end of each year following the date of grant. When stock options are exercised the Company issues new shares after receipt of exercise proceeds and taxes due, if any, from the grantee. The Company utilizes the Black-Scholes valuation model for estimating fair value of stock compensation for options awarded to officers and employees. Each grant is evaluated based upon assumptions at the time of grant. The assumptions were no dividend yield, expected volatility between 28.45% and 41.17%, risk-free interest rate of 2.0% to 3.8% and expected life of 5.0 to 7.0 years. The dividend yield of zero is based on the fact that the Company does not pay cash dividends and has no present intention to pay cash dividends. Expected volatility is estimated based on the Company’s historical experience over a period equivalent to the expected life in years. The risk-free interest rate is based on the U.S. Treasury constant maturity interest rate at the date of grant with a term consistent with the expected life of the options granted. The expected life calculation is based on the observed and expected time to exercise options by the employees. In January 2024, 12,200 shares of stock options were granted to an employee that will vest over the next four years. In January 2024, 20,330 shares of stock options were granted to an employee as part of a long-term incentive plan that will vest over the next five years. In January and May 2024, 12,780 shares of restricted stock were granted to employees that will vest over the next four years. In January and May 2024, 23,186 shares of restricted stock were granted to employees as part of a long-term incentive plan that will vest over the next five years. In March 2024, 6,704 shares of restricted stock were granted to employees under the terms of the 2022 long-term incentive plan. In January 2023, 15,960 shares of restricted stock were granted to employees that will vest over the next four years. In January 2023, 30,064 shares of restricted stock were granted to employees as part of a long-term incentive plan that will vest over the next five years. In March 2023, 4,544 shares of restricted stock were granted to employees under the terms of the 2021 long-term incentive plan. In January 2022, 14,896 shares of restricted stock were granted to employees that will vest over the next four years. In January 2022, 28,032 shares of restricted stock were granted to employees as part of a long-term incentive plan that will vest over the next five years. The number of common shares available for future issuance was 567,014 at December 31, 2024. In January 2023 and January 2022, 1,856 and 1,730 shares of stock, respectively, were granted to employees. The Company recorded the following stock compensation expense in its consolidated statements of income (in thousands):
| Years Ended December 31,
| 2024 |  | 2023 |  | 2022
Stock option grants | $ | 78 |  |  | 60 |  |  | 69 |
Restricted stock awards | 1,279 |  |  | 1,028 |  |  | 800 |
Employee stock grant | — |  |  | 50 |  |  | 50 |
Annual director stock award | 600 |  |  | 600 |  |  | 650 |
| $ | 1,957 |  |  | 1,738 |  |  | 1,569 |
A summary of changes in outstanding options is presented below (in thousands, except share and per share amounts):
Options | Number of Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Term (yrs) |  | Weighted Average Grant Date Fair Value(000's)
Outstanding at |  |  |  |  |  |  |
January 1, 2022 | 209,510 |  | $ | 18.97 |  |  | 4.8 |  | $ | 1,416 |
Exercised | (32,920) |  |  | $ | 12.54 |  |  |  |  | $ | (145) |
Outstanding at |  |  |  |  |  |  |
December 31, 2022 | 176,590 |  | $ | 20.17 |  |  | 4.4 |  | $ | 1,271 |
Exercised | (49,710) |  |  | $ | 20.61 |  |  |  |  | $ | (290) |
Outstanding at |  |  |  |  |  |  |
December 31, 2023 | 126,880 |  | $ | 20.00 |  |  | 3.5 |  | $ | 981 |
Granted | 32,530 |  | $ | 31.44 |  |  | 9.0 |  | $ | 400 |
Exercised | (16,420) |  |  | $ | 13.48 |  |  |  |  | $ | (100) |
Outstanding at |  |  |  |  |  |  |
December 31, 2024 | 142,990 |  | $ | 23.35 |  |  | 4.2 |  | $ | 1,281 |
Exercisable at |  |  |  |  |  |  |
December 31, 2024 | 113,510 |  | $ | 21.25 |  |  | 3.0 |  | $ | 918 |
Vested during twelve months ended |  |  |  |  |  |  |
December 31, 2024 | 3,050 |  |  |  |  |  | $ | 37 |
The following table summarizes information concerning stock options outstanding at December 31, 2024:
Range of Exercise Prices per Share | Shares under Option |  | Weighted Average Exercise Price |  | Weighted Average Remaining Life |
$15.57 - $18.76 | 14,840 |  | 15.58 |  |  | 0.9 |
$18.77 - $22.24 | 24,000 |  | 19.23 |  |  | 2.0 |
$22.25 - $22.99 | 71,620 |  | 22.66 |  |  | 3.5 |
$23.00 - $31.44 | 32,530 |  | 31.44 |  |  | 9.0 |
Total | 142,990 |  | $ | 23.35 |  |  | 4.2 | Years
The aggregate intrinsic value of exercisable in-the-money options was $1,068,000 and the aggregate intrinsic value of outstanding in-the-money options was $1,068,000 based on the market closing price of $30.63 on December 31, 2024 less exercise prices. Gains of $295,000 were realized by option holders during the year ended December 31, 2024. A summary of changes in restricted stock awards is presented below (in thousands, except share and per share amounts):
Restricted stock | Number Of Shares |  | Weighted Average Exercise Price |  | Weighted Average Remaining Term (yrs) |  | Weighted Average Grant Date Fair Value(000's)
Non-vested at January 1, 2022 | 92,148 |  | $ | 22.94 |  |  | 3.1 |  | $ | 2,114 |
Time-based awards granted | 14,896 |  | 28.90 |  |  |  |  | 431 |
Performance-based awards granted | 28,032 |  | 28.90 |  |  |  |  | 810 |
Forfeited | (2,726) |  |  | 23.15 |  |  |  |  | (63) |
Vested | (31,358) |  |  | 23.78 |  |  |  |  | (746) |
Non-vested at December 31, 2022 | 100,992 |  | $ | 25.21 |  |  | 3.0 |  | $ | 2,546 |
Time-based awards granted | 15,960 |  | 26.93 |  |  |  |  | 430 |
Performance-based awards granted | 34,608 |  | 26.96 |  |  |  |  | 933 |
Vested | (42,106) |  |  | 24.03 |  |  |  |  | (1,012) |
Non-vested at December 31, 2023 | 109,454 |  | $ | 26.47 |  |  | 2.8 |  | $ | 2,897 |
Time-based awards granted | 12,780 |  | 31.30 |  |  |  |  | 400 |
Performance-based awards granted | 29,890 |  | 31.06 |  |  |  |  | 928 |
Vested | (49,446) |  |  | 48.06 |  |  |  |  | (1,305) |
Non-vested at December 31, 2024 | 102,678 |  | $ | 28.44 |  |  | 2.7 |  | $ | 2,920 |
Total unrecognized compensation cost of restricted stock granted but not yet vested as of December 31, 2024 was $2,412,000 which is expected to be recognized over a weighted-average period of 2.6 years.

X
- References No definition available. + Details
Name: | us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of share-based payment arrangement. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 50 -Paragraph 1 -SubTopic 10 -Topic 718 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 718 -SubTopic 10 -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2 + Details
Name: | us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration